BACKGROUND: Percutaneous coronary intervention with drug-eluting stents (DES) has been increasingly used for revascularization of saphenous vein graft stenosis without strong clinical evidence favoring their use. Randomized controlled trials comparing DES versus bare-metal stents (BMS) in saphenous vein graft-percutaneous coronary intervention have been inconclusive.
P
ercutaneous coronary intervention (PCI) has been commonly used for revascularization of saphenous vein aortocoronary bypass graft (SVG) stenosis over the past decade.
1,2 Drug-eluting stents (DES) have been increasingly used for SVG-PCI without clear evidence favoring their use. 3 Both randomized trials and population-based studies comparing bare-metal stents (BMS) with DES have been inconclusive and conflicting. [4] [5] [6] [7] [8] This inconsistency in the results is thought to be because of relatively small sample size, short-term follow-up, and angiographic endpoints that were not clinically significant. Recently, one of the largest randomized controlled trials (RCT), DIVA (Drug-Eluting Stents Versus Bare-Metal Stents In Saphenous Vein Graft Angioplasty), compared contemporary DES with BMS in SVG-PCI and used target vessel failure as the primary end point, a composite of cardiac death, target vessel myocardial infarction (MI), and target vessel revascularization in contrast to some of the previous trials which used angiographic restenosis that may not be clinically relevant. 9 We present an updated meta-analysis of all the RCT published to date comparing DES with BMS in SVG-PCI with clinically significant endpoints that can enhance our understanding of the efficacy and safety of the 2 types of stents.
METHODS
The data, analytic methods, and study materials are available to other researchers for the purposes of reproducing the results or replicating the procedure.
Human subjects were not directly involved in this study. Therefore, no informed consent and Institutional Review Board approval was required.
Search Strategy
The systematic review and meta-analysis was done in compliance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines. 10 The initial search strategy was developed by 3 authors (Drs Patel, Bavishi, and Atti). We performed a systematic search, without language restriction, using PubMed, EMBASE, SCOPUS, Google Scholar, and ClinicalTrials.gov from inception to May 15, 2018 , for studies comparing clinical outcomes between BMS and DES in patients undergoing PCI for SVG lesions. We used the following keywords and medical subject heading: "drug-eluting stent," "DES," "bare metal stent," "BMS," "stent," "saphenous vein graft," "saphenous venous graft," "SVG," "saphenous graft, "randomized trials," and "randomized controlled trials." The reference lists of original studies, conference abstracts, and relevant review articles were further reviewed.
Study Selection
Studies were included if they fulfill the following criteria: (1) randomized controlled trials; (2) evaluated the efficacy and safety of DES versus BMS for SVG interventions; and (3) followup duration of at least 1 year. Three physician-reviewers (Drs Patel, Bavishi, and Atti) independently performed the literature search, reviewed the originally identified titles and abstracts, and selected studies for pooled analysis based on the inclusion criteria. Any disagreement was resolved by consensus.
Clinical Outcomes
We evaluated the following clinical outcomes: (1) major adverse cardiovascular events (MACE); (2) all-cause mortality; (3) cardiovascular mortality; (4) MI; (5) stent thrombosis; and (6) target vessel revascularization (TVR). Deaths attributed to cardiac causes were included under cardiovascular mortality. Studies reporting MACE defined it as the composite of death, MI, or TVR. Stent thrombosis was defined as definite or probable stent thrombosis according to the Academic Research Consortium criteria, and the trial-specific definitions for each outcome were used. TVR was defined by any repeat revascularization procedure (PCI or coronary artery bypass grafting [CABG] ) done in the venous graft conduit.
Statistical Analyses
The meta-analysis was done using Review Manager (RevMan), version 5.3; Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. Because of heterogeneity in the methodologies of the included studies and the types of stents used, a random effects model estimating the risk ratio (RR) and the estimated 95% CI of the above-mentioned outcomes were used. Meta-analysis was undertaken using the Mantel-Haenszel method. Heterogeneity was assessed using Higgins and Thompson I 2 statistic, with I 2 values of <25%, 25% to 75%, and >75% corresponding to low, moderate, and high levels of heterogeneity, respectively. Publication bias was visually estimated by funnel plots. A 2-tailed P<0.05 was considered statistically significant for all analyses. 
WHAT IS KNOWN

WHAT THE STUDY ADDS
• This meta-analysis of all the randomized controlled trials published to date resulted in a larger sample and also utilized clinically significant end points.
• There was no significant difference in mortality, target vessel revascularization, myocardial infarction, or stent thrombosis between drug-eluting stents and bare-metal stents in saphenous vein graft-percutaneous coronary intervention.
RESULTS
Search Results
A total of 504 articles were retrieved during the initial search ( Figure 1 ). A total of 451 articles were excluded based on review of title and abstract. An additional 49 reports were further excluded (observational studies, 6; review articles and meta-analysis, 9; short-term follow-up reports, 3; studies without outcomes or comparison groups of interest, 22; other, 9). Two RCTs were additionally selected (1 conference abstract and 1 after reviewing articles). Finally, 6 RCTs with a total of 1582 patients were eligible for review. The inter-reviewer agreement on study eligibility was 100%.
The clinical characteristics of the included studies are summarized in Table 1 . The angiographic/procedural characteristics of the included studies are summarized in Table 2 . A total of 797 and 785 patients were randomized to DES and BMS, respectively, for SVG-PCI. The duration of follow-up for the included RCTs ranged from 18 to 60 months. The mean age of the patient population ranged from 66±9 to 73±7 years. Five of the 6 included RCTs used first-generation DES, whereas DIVA included mostly second-generation DES (93%). [5] [6] [7] [8] [9] [10] The use of first-generation DES varied among the studies with SOS (Stenting of Saphenous Vein Grafts) and BASKET-SAVAGE (Basel Stent Kosten Effektivitäts TrialSaphenous Venous Graft Angioplasty Using Glycoprotein 2b/3a Receptor Inhibitors and Drug-Eluting Stents) using paclitaxel-eluting stents. DELAYED-RRISC (Death and Events at Long-Term Follow-Up Analysis: Extended Duration of the Reduction of Restenosis in Saphenous Vein Grafts With Cypher Stent) used sirolimus-eluting stents, whereas BASKET and ISAR-CABG (Is Drug-Eluting Stenting Associated With Improved Results in Coronary Artery Bypass Grafting) used both paclitaxel and sirolimus-eluting stents. The use of embolic protection devices was inconsistent among the studies, varying from <5% to 84%. SOS and ISAR-CABG had angiographic followup. DIVA was the only RCT that was blinded.
Clinical Outcomes
Major Adverse Cardiovascular Events There was no statistically significant difference between DES and BMS for MACE (RR, 0.83; 95% CI, 0.63-1.10; P=0.20). There was a high level of heterogeneity seen among the studies included (I 2 =77%).
Cardiovascular Mortality
There was no statistically significant difference in cardiovascular mortality (RR, 1.00; 95% CI, 0.64-1.57; P=0.99). I 2 of 30% reflects that the studies are moderately heterogeneous.
All-Cause Mortality
No significant difference in all-cause mortality was found between DES and BMS (RR, 1.11; 95% CI, 0.77-1.62; P=0.57). I 2 was 48%, suggestive of moderate heterogeneity.
MI and Stent Thrombosis
There were no statistically significant differences between DES and BMS for MI (RR, 0.74; 95% CI, 0.48-1.16; P=0. 19 ) and stent thrombosis (RR, 1.06; 95% CI, 0.42-2.65; P=0.90). The studies were moderately heterogeneous for both the outcomes (I 2 =50% and 51%, respectively).
Target Vessel Revascularization
There was no statistically significant difference in TVR between DES and BMS (RR, 0.73; 95% CI, 0.48-1.11; P=0.14). The heterogeneity was moderate to high (I 2 =75%).
The results of the meta-analysis are presented in Table 3 . Forest plots for the clinical outcomes are presented in Figure 2 . Funnel plot for visual inspection of publication bias is presented in Figure 3 .
DISCUSSION
The results of our meta-analysis showed that there was no significant difference between DES and BMS for MACE, all-cause mortality, cardiovascular mortality, TVR, stent thrombosis, or MI.
PCI emerged as a preferred choice for the treatment of SVG failure, constituting 6% of total PCI volume, as repeat CABG increases the risk of morbidity and mortality compared with the initial surgery. 3, 11, 12 PCI of the SVG is associated with increased risk, given the different pathophysiology of SVG, higher incidence of distal embolization of friable material, and increased risk of restenosis. 1 Initially, BMS were evaluated for use in SVG-PCI, but they were associated with a high rate of restenosis and also increased risk of MACE. 13, 14 Later, DES were studied owing to their proven benefit in reducing intimal hyperplasia and restenosis in native vessels, 15, 16 but similar results could not be translated in SVG-PCI. [16] [17] [18] [19] [20] In our analysis, DES did not have benefit over BMS for overall mortality. This was in line with most of the RCTs except DELAYED-RRISC which had shown the use of DES increased mortality risk. 6 However, this trial was underpowered to assess mortality and also dual antiplatelet therapy was terminated prematurely. 6 Our results are in contrast to a previous meta-analysis by Wiisanen et al 21 who had shown that DES was associated with improved mortality compared with BMS. Their analysis included only 4 small RCTs and also observational studies, whereas we focused on RCTs only and included 3 additional major studies providing a 6-fold larger randomized sample and with a minimal follow-up of at least 1 year. 21 There was no statistically significant difference between DES and BMS for MACE in the present study. This was consistent with the results of all the included RCTs except for BASKET and BASKET-SAVAGE, which reported lower MACE with DES. 5 Both the studies had small sample sizes, and BASKET-SAVAGE was terminated prematurely because of poor enrollment. The lower rate of MACE was driven by lower TVR events reported with DES in these 2 studies. We observed no statistically significant difference between DES and BMS for stent thrombosis and MI. This was evident in all the included RCTs and was also comparable to previous meta-analyses. 21, 22 The earlier first-generation DES were associated with increased risk of late stent thrombosis because of polymer triggered hypersensitivity reactions and late acquired malapposition. 19, [23] [24] [25] We observed no difference in the risk of TVR between DES and BMS. BASKET and BASKET-SAVAGE showed lower risk of TVR associated with DES. 5 This is probably related to the proven efficacy of DES in reducing neo-intimal hyperplasia. 26 Venous grafts are more susceptible to rapidly progressive atherosclerotic disease and once a graft starts degenerating, there is high risk of failure. 27 The antiproliferative effect of the DES can prevent stenosis of the stented segment, but it may not have any effect on the remaining unstented vessel that is susceptible to atherosclerotic blockage in the long term. This was evident in the contemporary real-world experience using data from clinical registries where lower risk of TVR observed during a short-term period after DES implantation was lost during long-term follow-up. 28, 29 Recently, the long-term results of the ISAR-CABG trial also showed that beneficial effects of DES over BMS observed during the early period were lost during the long-term follow-up at 5 years. 8 However, TVR was used as a secondary end point in the RCTs included. Most of the studies included in our analysis examined the outcomes for first-generation DES except DIVA which compared second-generation DES with contemporary BMS. Therefore, long-term randomized studies with adequate sample size are warranted to address some of these issues.
Newer generation DES have shown improved outcomes compared with both first-generation DES and BMS in native coronaries. 30, 31 However, a similar benefit was not found in treatment of SVG stenosis in the DIVA trial. 9 The primary outcome of the DIVA trial was target vessel failure, a composite of cardiac death, target vessel MI, and TVR which was similar in both DES and BMS groups. This is comparable to our findings, where we did not find any significant difference between DES and BMS for MACE (composite of death, MI, and TVR). In DIVA, TVR was a component of the primary outcome; hence, there is a possibility that the number of events occurring could have been underpowered to detect a statistically significant difference in TVR between the 2 types of stents. In contrast to some of the previous RCTs, DIVA utilized only clinical follow-up, thereby, minimizing the risk of unnecessary revascularization procedures because of angiographically observed restenosis. The trial investigators attributed the lack of benefit with DES to the higher rate of diabetes in the DIVA trial compared with prior trials and to the use of thin-strut BMS that were associated with lower risk of restenosis compared with the earlier thick-strut BMS used in previous SVG-PCI studies. 9 Finally, DES have been increasingly favored over BMS in PCI procedures including SVG interventions, whereas BMS have been gradually taken out from many catheterization laboratories in high-income countries. As the pathophysiology of atherosclerosis is different in venous grafts compared with native coronary arteries, novel strategies should be continuously explored. There is still a need for more randomized studies with longterm follow-up to evaluate if newer generation DES could improve outcomes in SVG-PCI. 
Limitations
The sample size of the studies included was small except ISAR-CABG and DIVA; thus, this meta-analysis may still be underpowered to detect the true clinical effects of the outcomes measured. Some studies used angiographic restenosis as the primary end point and were, therefore, underpowered to study outcomes, such as MACE and clinical TVR. Five of the 6 studies included were not blinded, increasing the risk for performing repeat procedures in patients with BMS because of perceived lower efficacy. There was wide variation in the duration of dual antiplatelet therapy between the 2 arms of included studies and also among studies. The majority of the study participants among the included studies were men, so generalizability of the present results to women should be made with caution. Two of the included trials, ISAR-CABG and SOS, utilized angiographic follow-up which has been shown to be associated with increased rates of restenosis and TVR events. 7, 8, 32 Most of the RCTs used first-generation DES; newer generation DES are shown to have improved outcomes over BMS in native coronary lesions. Furthermore, there was variation in the characteristics of the stents (type, size, diameter) utilized among the included studies.
Conclusions
In patients undergoing PCI for SVG lesions, our results showed that there was no significant difference 
